PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
KNSA Kiniksa Pharmaceuticals International
- 19.740
- +0.090+0.46%
Close Feb 14 16:00 ET
- 19.740
- 0.0000.00%
Post 16:20 ET
1.43BMarket Cap-164.50P/E (TTM)
20.320High19.580Low640.90KVolume19.920Open19.650Pre Close12.77MTurnover2.82%Turnover Ratio98.70P/E (Static)72.20MShares28.15052wk High3.26P/B447.99MFloat Cap16.56052wk Low--Dividend TTM22.69MShs Float32.880Historical High--Div YieldTTM3.77%Amplitude5.010Historical Low19.927Avg Price1Lot Size
About Kiniksa Pharmaceuticals International Company
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Company Profile
SymbolKNSA
Company NameKiniksa Pharmaceuticals International
Listing DateMay 24, 2018
Issue Price18.00
Founded2024
CEOMr. Sanj K. Patel
MarketNASDAQ
Employees297
Fiscal Year Ends12-31
Address23 Old Bond Street,3rd Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1S 4PZ
Phone44-781-431-9100
Websitehttps://www.kiniksa.com
Company Executives
- Name
- Position
- Salary
- Sanj K. Patel
- Chief Executive Officer and Chairman of the Board
- 5.30M
- Mark Ragosa
- Senior Vice President and Chief Financial Officer
- --
- Ross Moat
- Senior Vice President and Chief Commercial Officer
- --
- Michael R. Megna
- Chief Accounting Officer and Group Vice President, Finance
- --
- John F. Paolini, M.D.,PhD
- Senior Vice President and Chief Medical Officer
- 1.79M
- Eben Tessari
- Senior Vice President and Chief Operating Officer
- 1.75M
- Cantey Boyd
- Director
- --
- Dr. Felix J. Baker,PhD
- Lead Independent Director
- 411.06K
- Tracey L. McCain, Esq.
- Independent Director
- 365.36K
- Dr. Stephen R. Biggar,M.D.,PhD
- Independent Director
- 371.96K
- Thomas R. Malley
- Independent Director
- 380.36K
- Dr. Richard S. Levy,M.D.
- Independent Director
- 459.75K
- Kimberly J. Popovits
- Independent Director
- 362.66K
- G. Bradley Cole
- Independent Director
- 365.36K
- Dr. Barry D. Quart,Pharm.D.
- Independent Director
- 372.55K
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025